CIK is a novel strategy of cancer cell immunotherapy based on modification, manipulation, and co-opting of autologous or allogeneic primary CD3+ CD56- T cells and CD3+ CD56+ NKT cells [122–124], in which NKT cells can recognize tumor cells in a HLA-unrestricted manner [122, 125, 126]. This evidence concerns the gene NCAM1 and cancer.